Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3135-3141

  Sinha, Akhouri A ^a,c   Morgan, Jenifer L ^a   Buus, Ryan J ^a   Ewing, Stephen L ^b,c   Fernandes, Eduardo T ^a,c   Chap, Le ^a   Wilson, Michael J ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Gleason grade; Inhibitor stefin A; Prostate; Prostatectomy; Protease cathepsin B; Race

Indexed keywords

CATHEPSIN B;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER INVASION; CAUCASIAN; COMPUTER PROGRAM; CONTROLLED STUDY; ETHNICITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

AFRICAN AMERICANS; CATHEPSIN B; CYSTATINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM INVASIVENESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 35348946385     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Jiaquan X, Smigal C and Thun MJ: Cancer statistics. CA: A cancer journal for clinicians 56: 106-130, 2006.
2. Sanchez-Oritz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA and Pettaway CA: African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107: 75-82, 2006.
3. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A and Thun MJ: Cancer disparities by race/ethnicity and socioeconomic status. CA: A cancer journal for clinicians 54: 78-93, 2004.
4. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B and Amling CL: Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 101: 748-753, 2004.
5. Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK and McLeod DG: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 162: 394-397, 1999.
6. Latchamsetty KC, Kim J and Proter CR: Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black American men but not in white men: results from a consecutive series of 914 men. J Urol 175: 913-917, 2006.
7. Yang G, Addai J, Ittmann M, Wheeler TM and Thompson TM: Elevated caveolin-1 levels in African-American versus white American prostate cancer. Clin Cancer Res 6: 3430-3433, 2000.
8. Guo Y, Sigman DB, Borkowski A and Kyprianou N: Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate 42: 130-136, 2000.
9. Liotta LA and Stetler-Stevenson WG: Metalloproteinases and tumor progression. Semin Cancer Biol 1: 99-106, 1990.
10. Jedeszko C and Sloane BF: Cysteine cathepsins in human cancer. Biol Chem 385: 1017-1027, 2004.
11. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF: Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278, 1992.
12. Yan S and Sloane BF: Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem 384: 845-854, 2003.
13. Sinha AA, Jamuar MP, Wilson MJ, Rozhin J and Sloane BF: Plasma membrane association of cathepsin B in human prostate cancer: Biochemical and immunogold electron microscopic analysis. Prostate 49: 172-184, 2001.
14. Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Intern J Biol Markers 15: 84-89, 2000.
15. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL and Gleason DF: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in human prostate cancer. Cancer 94: 3141-3149, 2002.
16. Gleason DF: Histologic grading of prostate cancer. Hum Pathol 23: 273-279, 1992.
17. Epstein JI, Allsbrook JWC, Amin MB, Egevad LL and Committee IG: The 2005 International Society of Urologic Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29: 1228-1242, 2005.
18. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF and Gleason DF: The ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 48: 274-284, 2001.
19. Sinha AA, Quast BJ, Wilson MJ, Reddy PK, Gleason DF and Sloane BF: Co-distribution of pro and mature cathepsin B forms in human prostate tumors detected by confocal and immunofluorescence microscopy. Anat Rec 252: 281-289, 1998.
20. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M and Sloane BF: Immunohistochemical localization of cathepsin B in neoplastic human prostate. The Prostate 26: 171-178, 1995.
21. Humphrey PA and Walther PJ: Adenocarcinoma of the Prostate, Part II: Tissue prognosticators. Am J Clin Path 100: 256-269, 1993.
22. Witte MN, Kattan MW, Albani J, Sharp DS, Eastham JA and Morton RA Jr: Race is not an independent predictor of positive surgical margins after radical prostatectomy. Urol 54: 869-874, 1999.